Sarcopenia has been recently recognized as a disease for the purposes of coding (ICD-10-CM M62.84) and reimbursement [1, 2] . This acknowledgement has important implications for researchers, as this disease is related to malnutrition and frailty [3] , functional decline, high rate of hospitalization, loss of quality of life [4] and increased mortality [5] , but the definitive diagnostic [6] and therapeutic strategies [2] to counteract this reversible condition remain a challenge [7] .
The European Geriatric Medicine Society (EuGMS) is a leader in activities around sarcopenia in Europe and promoted the European Working Group on Sarcopenia in Older People (EWGSOP), which has proposed the most widely used algorithm for sarcopenia case finding and recommends assessment of sarcopenia in all geriatric patients and every healthcare setting [7] .
The EuGMS founded the Special Interest Group (SIG) on Sarcopenia in September 2015, and published the first special issue on sarcopenia in European Geriatric Medicine in 2016 [8] ; since then, the number of formal members of this interest group has increased to 74, making it the most extensive SIG of the EuGMS.
Staying in the lead of cutting-edge translational activities around sarcopenia, the EuGMS and the SIG on Sarcopenia are now launching the International Registry of patients with sarcopenia, among other initiatives, in an effort to bridge the gaps between research and clinical settings; and in line with the report from the International Conference on Frailty and Sarcopenia Research Task Force [2] and the World Health Organization's strategy to enhance initiatives towards optimal aging [9] .
To the best of our knowledge, this EuGMS initiative is the first registry of patients with sarcopenia. In Geriatric medicine, there are very few registries. For example, the EURECCA International Comparison is an European registry on treatment and survival of older patients with colon cancer, involving six European countries and 50,000 patients in its first decade [10] ; in Italy, the "Syncope and Dementia registry" is a prospective, observational multicenter study assessing the transient loss of consciousness in patients with dementia in usual care [11] .
Other fields of medicine have a higher number of registries, with a wide range of policies on research access. A systematic review in nephrology identified 144 renal registries, of which 22 provided public access for publications or reports and only 13 made anonymized patient data available to the external researchers, either by application and review of the proposed data usage or by user fees [12] . In surgery, 18 clinical registries that focus on the surgical quality have been described [13] . In rheumatology [14] , the main topic of registries is rare diseases; a systematic review identified 48 clinical registries about 23 different diseases, most of them classified as rare but they also include more common ones, such as psoriasis. In dermatology, 11 registries on survival after skin cancer, with a focus on the clinical adverse outcomes, have been described [15] .
The ultimate goal of the International Registry of patients with sarcopenia is to unify the efforts and observations of clinicians and researchers worldwide, [2] and provide ready access to the data for research purposes. However, the registry also has intermediate objectives:
1. To identify the population where sarcopenia is being assessed; Currently, some of the populations likely to present sarcopenia have not been well studied, such as patients hospitalized in acute [16, 17] and post-acute [8] healthcare settings or living in long-term care facilities [18] . 2. To assess the baseline characteristics of the patients with sarcopenia. 3. To evaluate and compare the tools and the cut-off values used in clinical practice to assess sarcopenia. The action research philosophy (i.e. applying research to clinical practice) [19] leaves information gaps about the assessment methods and the cut-off points to be used [6] . 4. To compare the data between countries and world regions [20] . 5. To create a collaborative network of researchers and clinical centers interested in combating sarcopenia. For example, 111 studies have been published from the data contained in the 18 clinical registries focused on the surgical quality [13] . In Spain, researchers who include data in FRENA (Factores de Riesgo y ENfermedad Arterial; in English, Risk Factors and Arterial Disease) form a collaborative group that has co-authored 16 publications to date from the registry data [21, 22] .
In the future, this registry could perhaps be used for quality assurance, as is the case in Germany for some cancer registries [23] . The centers involved are certified and included in the national comparative analysis of adherence to guidelines. They also actively contribute to many research projects, providing data on cancer etiology, screening programs, patient care and clinical outcomes of the population-based studies [23] .
The design and development of this Registry incorporated evidence from the epidemiological studies on sarcopenia [24] . The data collection was modeled after existing registries in other disciplines, in an effort to encourage participation and optimize management of the contributed data. Currently, the data collected (as available for each participating center) include muscle mass, strength and physical performance as well as the demographic and socio-economic information. This is an International Registry because the variables requested meet the criteria of most existing definitions: European Working Group on Sarcopenia in Older People [7] and the 2018 consensus, in process of publication, Asian Working Group for Sarcopenia (AWGS) [25] , International Working Group on Sarcopenia (IWGS) [26] , Foundation for the National Institutes of Health definition (FNIH) [27] , Society on Sarcopenia, Cachexia and Wasting Disorders (SSCWD) [28] , European Society for Clinical Nutrition and the Metabolism-Special Interest Group [29] . Moreover, all races/ethnicities and countries have been represented and users decide and specify the cut-off points used. The term "European", used twice in the website, should not limit the use of the Registry worldwide.
The initial reception by researchers from countries outside of Europe is promising and the Publication plan for projects proposed by the users is a work in progress. Collaborative partnerships with researchers and clinicians from scientific societies worldwide are expected and welcome.
One of the premises for developing the International Registry of patients with sarcopenia was that the value of the Registry must compensate for the effort and time invested in data recording. All participants in the Registry will contribute to the knowledge on sarcopenia. In addition, those who substantially contribute to the Registry could submit a research proposal based on the data of the registry that will be checked and approved by a scientific committee. These active members of the Registry will also be eligible to join the Registry's network of active researchers, including leaders of the SIG on Sarcopenia, EuGMS and other key groups working to improve the geriatric care.
Participation requires completion of a user profile (https :// www.e-clini cal.org/sarco penia /), which includes information on the clinical setting, assessment methods and the cut-off points used. After this brief (~ 5-min) step, patient data can be entered freely, with no limitations on the number of cases included.
Measures to ensure the quality of data recording as much as possible have been adopted. Internal caution measures related to the structure of the website were planned during the design and development of the Registry. External caution measures involve the Working Group on the International Registry and the eventual network of users. These measures are detailed as follows:
1. Internal caution measures: the design and development of the Registry website.
1.1 Each researcher is identified individually and is responsible for his or her own data entry and procedures; when a new user from a center already listed in the registry accesses the platform, this individual must again enter the identifying details for that center. 1.2 There is a contract in the first page of the Registry; by saving this form, the investigator agrees to the terms and conditions. These include, among others, being responsible for "the objectives, basic methodology and results"; moreover, after a data entry session, the researcher reaffirms this contract by responding to the following prompt: "I hereby confirm that the data contained in this visit are correct and complete". 1.3 To ensure the veracity of data, the design of the Registry makes it mandatory to enter the complete patient data "one by one", avoiding approaches such as uploading the data fields completed offline (e.g., in Excel or.css format) for multiple patients. The International Registry of patients with sarcopenia is expected to become a long-term source of data to inform the best-practice care of our aging population and to develop international research projects to advance our knowledge of this debilitating but reversible disease.
